



**HAL**  
open science

# **Mycobacterium abscessus pneumonia in a South Pacific islander**

Michael Phelippeau, Didier Musso, Michel Drancourt

► **To cite this version:**

Michael Phelippeau, Didier Musso, Michel Drancourt. Mycobacterium abscessus pneumonia in a South Pacific islander. *Journal of Microbiology, Immunology and Infection*, 2017, 50 (3), pp.393-394. 10.1016/j.jmii.2015.01.008 . hal-01773989

**HAL Id: hal-01773989**

**<https://hal.science/hal-01773989>**

Submitted on 24 Apr 2018

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: [www.e-jmii.com](http://www.e-jmii.com)

## CORRESPONDENCE

# *Mycobacterium abscessus* pneumonia in a South Pacific islander



Dear Editor,

Community-acquired pneumonia (CAP) is an important cause of morbidity and mortality in the Asia Pacific region.<sup>1</sup> In this region, the pathogens associated with CAP are rarely identified.<sup>1</sup> Nontuberculous mycobacteria (NTM), including *Mycobacterium abscessus*, are increasingly recognized as opportunistic pathogens responsible for respiratory tract infections.<sup>2</sup> Because NTM culture and identification is not routinely performed in most of the Pacific islands, NTM infections are underestimated.

To highlight the interest in identifying the etiological agents of CAP in the Pacific, we herein present the case of a French Polynesian man who fulfilled the American Thoracic Society criteria<sup>2</sup> for *M. abscessus* lung infection. Signed informed consent was obtained from the patient, and the French Polynesia Committee for Ethics approved this study.

A 77-year-old chronic obstructive pulmonary disease patient was admitted in May 2014 to our hospital with severe hypoxemia, cough, increased sputum purulence, and recurrent fever episodes since January 2014 after sequential amoxicillin–clavulanate and moxifloxacin treatments. A heavy ex-smoker, he received inhaled salmeterol/fluticasone and azithromycin long-term prophylaxis for 2 years. Computed tomography scanner showed large bullous emphysema and bilateral consolidations. Eight sputum specimens were collected from May 2014 to July 2014; all specimens were acid-fast bacilli (AFB) negative at direct examination, four yielded AFB colonies on Löwenstein–Jensen media (bioMérieux, La-Balme-les-Grottes, France) incubated at 37°C in a 5% CO<sub>2</sub> atmosphere. Isolates were identified as *M. abscessus* by hybridization using commercial probes (GenoType *Mycobacterium* CM/AS, Hain Lifescience, Nehren, Germany). The identification was confirmed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) with  $1.65 \pm 0.31$  log scores for *M. abscessus* DSM 44196<sup>T</sup> (Bruker Mycobacteria Library version v2.0, Bruker Daltonics,

Bremen, Germany). Further 16S ribosomal RNA, partial *rpoB* gene sequencing,<sup>3</sup> and multispacer typing<sup>4</sup> characterized the four isolates as belonging to the *M. abscessus* subsp. *abscessus* group.

The four positive sputum specimens were not consecutively collected and were identified during different processes and thus an in-laboratory contamination was unlikely.

As pulmonary rehabilitation (oxygen, chest physiotherapy, and protein diet) improved the respiratory function, we decided to stop azithromycin and delay cefoxitin and amikacin therapy. The patient left the hospital by mid-August 2014 and 6 months after the diagnosis, the patient is under medical surveillance for long-term follow-up, as previously reported.<sup>5</sup>

This case illustrates that NTM should be considered as etiological agents of CAP in the Asia Pacific region and that *M. abscessus* is present in remote South Pacific islands where it can act as an opportunistic respiratory tract pathogen.

Culture and identification of NTM in respiratory tract specimens is strongly advised, including rapid MALDI-TOF MS identification, in order to guide medical management of patients and monitoring of NTM in these tropical islands. In addition, the identification of etiological agents of CAP may prevent or delay the emergence of antibiotic resistance in the Asia Pacific region.

## Conflicts of interest

Authors declare no conflict of interest.

## References

1. Song JH, Thamlikitkul V, Hsueh PR. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. *Int J Antimicrob Agents* 2011;**38**: 108–17.

<http://dx.doi.org/10.1016/j.jmii.2015.01.008>

1684-1182/Copyright © 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

2. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 2007;175:367–416.
3. Adékambi T, Colson P, Drancourt M. *rpoB*-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria. *J Clin Microbiol* 2003;41:5699–708.
4. Sassi M, Ben Kahla I, Drancourt M. *Mycobacterium abscessus* multispacer sequence typing. *BMC Microbiol* 2013;13:3.
5. Pang YK, Ngeow YF, Wong YL, Liam CK. *Mycobacterium abscessus*—to treat or not to treat. *Respirol Case Rep* 2013;1:31–3.

Michael Phelippeau  
*Unité de Recherche sur les Maladies Infectieuses et  
Tropicales Émergentes, Unité Mixte de Recherche, Centre  
National de Recherche Scientifique, 6236-Institut de  
Recherche pour le Développement, 198,  
Aix-Marseille-Université, Méditerranée Infection,  
Marseille, France*

Didier Musso\*  
*Pôle de Recherche et de Veille sur les Maladies Infectieuses  
Émergentes, Institut Louis Malardé, Tahiti, French  
Polynesia*

Michel Drancourt  
*Unité de Recherche sur les Maladies Infectieuses et  
Tropicales Émergentes, Unité Mixte de Recherche, Centre  
National de Recherche Scientifique, 6236-Institut de  
Recherche pour le Développement, 198, Aix-Marseille-  
Université, Méditerranée Infection, Marseille, France*

\*Corresponding author. Institut Louis Malardé, P.O. Box 30,  
98713 Papeete, Tahiti, French Polynesia.  
E-mail address: [dmusso@ilm.pf](mailto:dmusso@ilm.pf) (D. Musso)

23 December 2014  
Available online 30 January 2015